Advancing regenerative medicine requires not only scientific innovation, but also IP protection. As so, patent filing consists a key milestone supporting the journey of new technologies from the laboratory to the clinic.
A patent application covering the fetal-inspired regenerative biomaterial platform for the treatment of intervertebral disc degeneration and associated low back pain - the foundation of Fetalix's technology - has been filed.
The invention is based on a decellularized extracellular matrix derived from fetal tissue. This biomaterial is characterized by a unique composition rich in specific collagen types and is designed to interact with the patient’s own disc cells to stimulate regenerative activity. Preclinical findings demonstrate that it promotes the production of key extracellular matrix components essential for healthy disc structure and function.
The patent also covers the formulation and manufacturing of the biomaterial into injectable pharmaceutical compositions, including microparticle and hydrogel-based formats designed for minimally-invasive intradiscal administration.
In the biotechnology sector, patents play a central role in enabling innovation by protecting new discoveries and supporting their development into clinical applications. They also establish a framework for collaboration and investment, essential to advancing biomedical technologies from bench to bedside.
This milestone marks an important stepping stone in the maturation of the technology now being advanced by Fetalix and its progression toward clinical and industrial development.
December 12, 2019
